LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Blood Test Prior to CAR T-Cell Therapy Could ID Patients at Risk for Neurotoxicity

By LabMedica International staff writers
Posted on 23 Sep 2022
Print article
Image: Blood test before CAR T-Cell treatment can identify patients likely to develop neurotoxicity (Photo courtesy of Unsplash)
Image: Blood test before CAR T-Cell treatment can identify patients likely to develop neurotoxicity (Photo courtesy of Unsplash)

Neurologic complications are common following treatment with chimeric antigen receptor (CAR) T cells, with an estimated 40-60% of patients developing immune effector cell–associated neurotoxicity syndrome (ICANS). Neurotoxic symptoms typically occur 3-9 days after infusion. While these side effects are generally low-grade, morbidity and mortality can occur with higher grade symptoms. Encephalopathy, aphasia and cerebral edema can occur. Now, a small study has demonstrated that a simple blood test before treatment can help identify patients who may be more likely to develop this adverse side effect.

Elevated levels of a protein called neurofilament light chain (NfL) have been observe in multiple neurodegenerative and neuroinflammatory diseases, suggesting to researchers at the Washington University School of Medicine in St. Louis (St. Louis, MO, USA) that it could be a biomarker for ICANS in patients set to undergo CAR T-cell treatment. The retrospective study included 30 patients out of which 12 patients were women and 18 were men. The median age was 64. NfL levels were measured at baseline (prior to lymphodepletion), during lymphodepletion, and days 1, 3, 7, 14 and 30 after infusion. Elevated NfL levels prior to lymphodepletion were markedly higher among patients who developed ICANS - 87.6 pg/mL for any ICANS vs. 29.4 pg/mL without ICANS (P < .001). Sensitivity and specificity of the test were 91% and 95%, respectively. NfL levels remained elevated through day 30.

“Our study suggests that some patients receiving CAR-T cell therapy have previously undetected damage to neurons present at baseline, before we even begin preparing them for this treatment,” lead author Omar H. Butt, MD, PhD, an instructor in oncology at the Washington University School of Medicine, said in a press release. “We don’t know the origin of this damage, but it appears to predispose them to developing neurotoxic complications. If we understand who is at risk of these complications, we can take early steps to prevent it or reduce the severity.”

Related Links:
Washington University School of Medicine in St. Louis 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more